Author: NewsCancer

Archie Goodburn, who has brain cancer and finished 7th in the men’s 50m breaststroke final at the Commonwealth Games, wants for the disease to get ‘the funding it deserves’.

Melanoma is a highly aggressive malignancy in which dysregulated ubiquitin-dependent signaling contributes to tumor progression. OTUD4 is frequently downregulated in melanoma, but the functional significance of this alteration remains unclear. Here, we identify OTUD4 as a dual-mode deubiquitinase that suppresses melanoma progression by coordinating K48- and K63-linked polyubiquitination. OTUD4 directly binds and stabilizes CYLD by counteracting K48-linked polyubiquitination, whereas it independently binds BCL3 and counteracts BCL3 K63-linked polyubiquitination. OTUD4 depletion promotes BCL3 ubiquitination and nuclear translocation in melanoma cells, leading to increased melanoma cell proliferation and tumor growth in clonogenic and xenograft assays. Clinically, expression of OTUD4 and CYLD progressively…

Johnson & Johnson (J&J) has offered to pay as much as $5.5bn (£4.14bn) to resolve tens of thousands of lawsuits in the US alleging that its baby powder and other products containing talcum cause ovarian cancer.The proposed landmark settlement aims to close a long-running legal battle that has weighed on the New Jersey-based healthcare giant for years.J&J has denied that its talc-based products caused cancer and has changed the formula of its widely used baby powder.Erik Haas, the firm’s vice president of litigation said on Monday, external that the allegations are “meritless” and that J&J was willing to settle in…

Inhibition of stromal TRAP1 suppresses BC progressionTo assess the contribution of TRAP1 to BC growth, we evaluated the anticancer activity of gamitrinib, a TRAP1 inhibitor currently in a phase I clinical trial.17,28,29 We examined its efficacy in two BC models: nude mice bearing orthotopic xenografts of triple-negative BC cells derived from the human BC cell line MDA-MB-231, and mammary tumor virus-polyoma middle T-antigen (MMTV-PyMT) transgenic mice, a spontaneous BC model. Gamitrinib inhibited tumor growth significantly in both models (Supplementary Fig. 1a–h). To delineate whether these antitumor activities involved the tumor microenvironment (TME), we compared the antitumor activity of gamitrinib in…

Breast CSCs are enriched in the circulation and on arrival in the lungOur fluorescent lentiviral CSC reporter (SORE6>FP) dynamically reports on stemness through activation of an artificial enhancer (‘SORE6’) by the stemness master transcription factors OCT4 and SOX2 or their paralogues14,15. A control construct lacking the SORE6 enhancer but retaining the minimal CMV promoter (minCMV) is used for gating or thresholding (Fig. 1a and Extended Data Fig. 1a). The destabilized mCherry has a short half-life of ~1.4 h (Extended Data Fig. 1b), which confers high selectivity and temporal resolution to the reporter. For this study, tumour cells were transduced with a…

The FDA has approved SimpleScreen™ CRC, a blood-based screening option, for use among adults 45 years and older who are at an average risk of developing colorectal cancer (CRC), according to a press release from the developer, Freenome, Inc.1The regulatory decision indicates that SimpleScreen CRC fulfills the coverage criteria for Medicare. Additionally, the screening option is anticipated to be incorporated into the American Cancer Society guidelines by name.How does SimpleScreen CRC work?Developers engineered SimpleScreen CRC to detect signals related to CRC based on cell-free DNA (cfDNA) in the blood. A positive result demonstrates that a signal was detected along with…

In an Around the Practice program hosted by CancerNetwork®, a panel of experts in thoracic oncology convened to discuss how to properly choose and sequence front-line therapeutic options for patients with advanced non–small cell lung cancer (NSCLC) harboring EGFR mutations. The group weighed the efficacy, safety, and administration profiles of regimens including osimertinib (Tagrisso) monotherapy in the phase 3 FLAURA trial (NCT02296125), osimertinib plus platinum-based chemotherapy and pemetrexed in the phase 3 FLAURA2 trial (NCT04035486), and amivantamab-vmjw (Rybrevant) plus lazertinib (Lazcluze) in the phase 3 MARIPOSA trial (NCT04487080).1-3 Furthermore, they discussed the adequate conditions for selecting one approach over another…

Sebastien A, Jacques F, Isabelle S, Ariana Z, Ahmedin J, Freddie B. Bladder Cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2016;71:96–108.Thomas WF, Philippe ES, Neeraj A, Rick B, Stephen AB, Mark KB, et al. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18:329–54.Prashant M, David CC. Mitochondrial dynamics and inheritance during cell division, development and disease. Nat Rev Mol Cell Biol. 2014;15:634–46.Article  Google Scholar  J Alfred W, Harman Max B, Richard C, Eva MC, Nigel CC, Georgios G, et al. European Association of Urology Guidelines on Muscle-invasive and…

Because the all-oral regimen of decitabine/cedazuridine (DEC-C; Inqovi) plus venetoclax (Venclexta) pairs an oral hypomethylating HMA backbone with venetoclax, gastrointestinal adverse events (AEs) can directly threaten adherence. CancerNetwork® spoke with Courtney D. DiNardo, MD, MSCE, professor in the Department of Leukemia and Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston; and Michael R. Savona, MD, professor of internal medicine and cancer biology and director of the Hematologic Malignancies Research and Early Therapy Program at Vanderbilt University Medical Center, about the specific supportive care and antiemetic strategies they use to help patients stay on…

Adjuvant ensartinib (Ensacove) significantly improved disease-free survival (DFS) vs placebo in patients with completely resected, ALK-positive stage IB to IIIB non–small cell lung cancer (NSCLC), according to results from the phase 3 ELEVATE trial (NCT05341583) published in The New England Journal of Medicine.What was the efficacy of ensartinib in the ELEVATE trial?Among patients with stage II to IIIB disease, the percentage of those who were alive and disease free at 24 months—the primary end point—was 86.4% with ensartinib vs 53.5% with placebo (HR for disease recurrence or death, 0.20; 95% CI, 0.11-0.38; P <.001). The median DFS was not calculable…